Sign In
Buy SPRB
$42.83
-0.540 (-1.25%)
At Close: Jul 31, 2026
Spruce Biosciences (NASDAQ:SPRB) Rating Lowered to Market Perform at SVB Leerink
12:22pm, Tuesday, 16'th Nov 2021 Transcript Daily
Spruce Biosciences (NASDAQ:SPRB) was downgraded by research analysts at SVB Leerink to a market perform rating in a research report issued on Tuesday, Stock Target Advisor reports. They currently have a $5.00 price objective on the stock, down from their previous price objective of $35.00. SVB Leerinks target price points to a potential upside of []
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
09:05pm, Monday, 15'th Nov 2021 Business Wire
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
Spruce Biosciences Appoints Mike Grey as Interim CEO
09:01pm, Monday, 15'th Nov 2021 Business Wire
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences Appoints Mike Grey as Interim CEO
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
11:30am, Friday, 06'th Aug 2021
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
08:07am, Thursday, 24'th Jun 2021
Dr. Ways' Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce's Goal to Expand Portfolio of Indications for Tildacerfont San Francisco, Cali
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
08:02am, Thursday, 24'th Jun 2021
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
08:05am, Monday, 21'st Jun 2021
Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalization in Key Hormone Biomar
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
08:03am, Monday, 21'st Jun 2021
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #ECE2021--Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
04:05pm, Wednesday, 12'th May 2021
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
04:05pm, Monday, 22'nd Mar 2021
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes
04:05pm, Thursday, 17'th Dec 2020
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes
